Ohmx™ Powering Protein Detection



FOR IMMEDIATE RELEASE

Contacts:
For Ohmx Corporation:
Dimitra Georganopoulou
Tel: (847) 491-8513
Fax: (847) 491-8510
dimitra@ohmx.com

Ohmx to participate in the 2013 AACC Annual Meeting

Evanston IL, February 28th 2013 – Ohmx Corporation, a bioelectronic detection company focused on developing a Point-of-Care analyzer for monitoring of chronic diseases, is pleased to announce the submission of a poster to the AACC Annual Meeting. Upon acceptance, this abstract will be presented as a poster at the Annual Meeting in Houston held from July 28th to August 1st 2013.

ABSTRACT:
Accurate Point-of-Care Hemoglobin A1C test using a low-cost bioelectronic single-measurement technology

Background
Hemoglobin A1c (HbA1c) is a stable hemoglobin derivative that results from the non-enzymatic glycation of the N-terminal valine on the beta chains. It serves as a good biomarker for monitoring glycemic control since it correlates linearly with the average blood glucose level over the lifespan of RBC's (2 to 3 months). Monitoring HbA1c is currently used to inform treatment decisions, to ensure compliance, and to help evaluate if patients are meeting their clinical goals. Since 2010, it is also the preferred method for diagnosing both Type II diabetes and pre-diabetes. Since HbA1c is measured as the percentage of total hemoglobin, most HbA1c tests are composed of two measurements; one to measure the glycated hemoglobin and the other to measure the total hemoglobin. Ohmx presents here the clinical validation for an innovative single measurement approach for quantifying HbA1c.*

Methods
Total hemoglobin capture antibody was immobilized on magnetic beads and used to equally bind all variants of hemoglobin in the sample. The captured HbA1c then binds to a specific probe antibody that is tagged with alkaline phosphatase (AP) forming an immune sandwich complex. This target-antibody complex is then used to generate an in-situ surrogate target which is enzymatically enhanced producing an amplified substrate. The amplified substrate is further quantified using a bioelectronic measurement. We 8 commercially available calibrators with HbA1c concentrations varying from 2.7%(6.0 mmol/mol) to 19.8%(192.9 mmol/mol) and established a standard curve directly correlating the electronic signal with the ratio of HbA1c. To verify the functionality of our HbA1c assay, we compared the results from 100 clinical whole blood samples with those values obtained by a BioRad clinical immunoanalyzer Variant II Turbo.

Results
The total assay time of our HbA1c test is <5minutes with a linear response ranging from 2.7% (6.0 mmol/mol) to 19.8% (192.9 mmol/mol). The single-measurement based signal improves the assay's reproducibility, with intraday precision CV less than 3% and interday precision CV less than 5%. The Ohmx assay has been clinical validated with 100 clinical

samples, and compared with data collected with BioRad clinical immunoanalyzer showing high correlation (R^2= 0.94).

Conclusions

There is excellent correlation between the data acquired by the single measurement Ohmx HbA1c test and the NGSP certified Biorad assay. The Ohmx technology is applicable for a variety of different analytes including ultrasensitive detection for proteins such as Troponin I and Thyroid Stimulating Hormone (TSH), also for small molecules such as Flavin Adenine Dinucleotide (FAD), lipid panel and other targets.

*Assay currently under development and not for clinical use

About the Company:

Ohmx is a clinical diagnostics company that is developing a low-cost, bioelectronic, Point-Of-Care (POC) reader that quantifies analytes from a low-volume biological sample (e.g. whole blood, urine, semen, prostatic fluid, etc). Ohmx's market entry strategy is based on a portable blood analyzer to assist clinicians with the diagnosis and monitoring of patients with chronic diseases in the POL (physician office lab) setting. The Ohmx POC device will enable doctors to quickly and cost-effectively diagnose, monitor and better manage patients with chronic diseases. The company's initial focus is on the diabetes market.

This press release contains forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from the results identified or implied in any forward-looking statement. These statements are based on our views as of the date they are made with respect to future results or events. The Company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results or events expressed or implied therein will not be realized.